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In this issue of Transplant International, two separate
groups, one from China and one from northern Europe,
present their retrospective experiences and results in ABO-
incompatible (ABOin) deceased donor liver transplantation
(DDLT) in adult recipients [1,2]. Both groups conclude
that ABOin DDLT might be life-saving and might be used
in urgent cases.
In the study by the Sun Yat-sen University group from
Guangzhou, China [2], in a population of recipients suffer-
ing from acute hepatitis B virus liver failure, ABOin graft
survival was 28% at 3 years, compared with 66.5% and
71% for ABO compatible (ABOc) and ABO identical
(ABOid) grafts, respectively (P < 0.05). The increased rate
of failures in ABOin DDLT was related to vascular throm-
bosis and biliary complications. In this Asian series, 77% of
the recipients were blood group O patients receiving non-
O grafts, and the number of A2 ABOin DDLT was not
determined. The immunosuppression was quite classical,
associating basiliximab, calcineurin inhibitors, mycopheno-
late mofetil and steroids [2]. The second study by Thorsen
et al. [1] reported the experience in ABOin DDLT from
two centres of Norway and Sweden. In 88% of the cases,
this European series included blood group O patients
receiving non-O grafts. Considering global patient survivals
of the whole series, their results were excellent, with patient
survivals at 79% and 75% at 3 and 5 years, respectively.
However, these patient survivals came at the price of a high
rate of vascular and biliary complications and a high rate of
retransplantations. The graft survivals of the A2 ABOin
DDLT were slightly better (although statistically nonsignifi-
cant due to the small sample size) than the non-A2 ABOin
DDLT (80% vs. 60% at 1 year and 67% vs. 48% at 3 years,
respectively) [1].
In contrast to other types of transplanted organs, the
liver graft is somehow protected against preformed anti-
bodies. It has been established for decades that liver trans-
plantation against blood group is possible both in children
and in adult recipients, with prolonged graft survivals with-
out rejection in some cases [3]. Pretransplant lymphocyto-
toxic cross-match is not considered before DDLT by most
groups [4]. Combined liver and kidney transplantation has
been advocated to allow kidney transplantation in highly
sensitized cross-match positive kidney candidates [5]. In
the 80s of last century, ABOin DDLT was regularly per-
formed to save patients with fulminant hepatic failure,
either as a definitive treatment or as a bridge to ABOc
DDLT [6]. However, with the success of DDLT and the
increased waiting lists, it was considered that ABOin graft
survival was not sufficient to ethically justify this policy. As
a consequence, in most allocation schemes, ABOin DDLT
788 © 2015 Steunstichting ESOT 28 (2015) 788–789
Transplant International ISSN 0934-0874
was forbidden, even in urgent cases. The eurotransplant
organization applied this policy in the 90s of last
century [7].
In the meantime, in countries where DDLT is not avail-
able, living donor liver transplantation (LDLT) has been
established first in children and afterwards in adults. In
these countries, protocols of ABOin LDLT have been suc-
cessfully developed, with excellent graft survival rates at
the price of heavy immunosuppressive regimens and a
higher risk of biliary complications [4]. In these countries,
ABOin LDLT remains the exception, and if a suitable
ABOc living donor is available, this ABOc donor is chosen
for donation. Ethically, in these programmes, ABOin
LDLT is justified when no ABOc living donor is available
as there is no possibility of ABOc DDLT and because AB-
Oin LDLT does not decrease the chances of other compati-
ble candidates waiting for DDLT. Indeed, these ethical
arguments justify the starting up of ABOin living donor
kidney transplantation programmes in both Eastern and
Western countries [8].
In the developed world, we are facing an increasing
deceased liver graft shortage. We are now using high-risk
(aged donors, steatotic liver grafts, donation after circula-
tory death) deceased grafts to partially overcome this prob-
lem [9,10]. ABOc LDLT is also regularly performed, but
ABOin DDLT is not a part of the solution. Indeed, it is the
contrary, as demonstrated by Thorsen et al. [1], that ABO-
in DDLT often requires retransplantation to achieve suffi-
cient survival rates, and therefore, ABOin increases the
deceased liver graft shortage. The only reason to perform
ABOin DDLT that could be ethically acceptable is when an
ABOc, or better still, an ABOid recipient, cannot be found
for a specific liver graft. But apart from the rare case of a
blood group AB donor with no potential compatible blood
group AB candidate, I doubt that in the modern era, no
suitable ABOc recipient can be found for the other blood
group donors. I do agree that when used as a bridge to
ABOc DDLT, ABOin DDLT might be life-saving, but it is
at the price of an increased mortality risk for the other
ABOc patients on the waiting lists.
In the two series of ABOin DDLT reported in this issue,
blood group O recipients represented the vast majority of
patients requiring ABOin DDLT [1,2]. And it seems clear
that the O liver candidates might have a longer waiting
time than other blood groups. The reason for this fact is
not purely medical; as to my knowledge, there is no reason
for the blood group O population to have an increased sus-
ceptibility to liver diseases or a decreased rate of organ
donation. The only logical reason is that these blood group
O liver transplant candidates are disadvantaged by the liver
graft allocation if the use of ABOc DDLT in some urgent or
less urgent cases is allowed. Any blood group O deceased
liver graft transplanted in an ABOc but not ABOid recipi-
ent increases the waiting time and the mortality of blood
group O candidates.
Finally, Thorsen et al. confirmed that A2 to O ABOin
DDLT might provide equivalent results as ABOid DDLT
[1,11], but before implementing a policy of performing A2
to O ABOin DDLT, it has to be demonstrated that the
waiting time and mortality risk of blood group O patients
is significantly higher than blood group A DDLT candi-
dates.
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